Targeting CXCR4 effectively mobilizes AML cells to the peripheral blood, prevents extramedullary organ infiltration and metastasis, and exhibits significant anti-leukemia efficacy with minimal toxic side effects, suggesting its potential as a personalized therapeutic target for AML [97,98]. This evidence concerns the gene CXCR4 and acute myeloid leukemia.